Ogier advises Cure Genetics on USD$60 million Series B funding

Ogier's corporate team has acted as British Virgin Islands and Cayman Islands counsel to Suzhou Cure Genetics Co Ltd (Cure Genetics) for its USD$60 million Series B fund raising on 5 January 2022.

The investors in this round of funding included Advantech Capital, Oriza Holdings, Blue Ocean Capital and Qiming Ventures Partners, with China Renaissance as the exclusive financial advisor.

Cure Genetics, headquartered in Suzhou, China, is a biotechnology company specialising in developing gene therapy. The funding raised would enable Cure Genetics to advance its clinical development of therapeutic pipelines for hematologic and solid tumours, and to enhance international collaborations based in its innovative AAV serotype screening platform and gene editing products.

The Ogier team, based in Hong Kong, was led by partner Cecilia Li with support from the firm's global head of Corporate, Nathan Powell, and paralegal Vicky Wu.